Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLNNASDAQ:CNATNASDAQ:CWBRNASDAQ:EVFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/ACNATConatus Pharmaceuticals$0.00$1.00$0.23▼$1.07$10K1.841.28 million shs40 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AEVFMEvofem Biosciences$0.01$0.01$0.01▼$0.02$1.19M-0.92435,993 shs39,482 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-74.79%CNATConatus Pharmaceuticals0.00%-98.31%-99.00%-98.93%-99.90%CWBRCohBar0.00%0.00%0.00%0.00%-18.00%EVFMEvofem Biosciences0.00%+6.38%+6.38%+3.09%+4.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem Biosciences0.5997 of 5 stars0.03.00.04.80.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/ACNATConatus Pharmaceuticals 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09CNATConatus Pharmaceuticals$21.72M0.00N/AN/A$0.53 per share0.00CWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05CNATConatus PharmaceuticalsN/A16.2816.28CWBRCohBarN/AN/AN/AEVFMEvofem BiosciencesN/A0.110.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%CNATConatus Pharmaceuticals15.20%CWBRCohBar2.47%EVFMEvofem Biosciences0.22%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%CNATConatus Pharmaceuticals11.30%CWBRCohBar6.51%EVFMEvofem Biosciences0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableCWBRCohBar102.91 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableCNAT, ASLN, CWBR, and EVFM HeadlinesRecent News About These CompaniesEvofem Biosciences, Inc. (EVFM) - Yahoo FinanceJuly 5 at 8:58 AM | finance.yahoo.comWindtree Contracts Chinese Firm to Make Evofem's ContraceptiveJune 26, 2025 | marketwatch.comEvofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug StoreJune 23, 2025 | prnewswire.comEvofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of DirectorsJune 9, 2025 | businesswire.comEvofem Signs SOLOSEC License Agreement for Middle East with Pharma 1May 21, 2025 | prnewswire.comEvofem Biosciences Inc. Q1 Earnings SummaryMay 17, 2025 | nasdaq.comEvofem Biosciences Reports Q1 2025 EarningsMay 16, 2025 | tipranks.comEvofem Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | prnewswire.comEvofem Biosciences Amends Agreement with UAE PartnerMay 8, 2025 | tipranks.comEvofem Biosciences to Present at Emerging Growth ConferenceApril 14, 2025 | prnewswire.comEvofem Biosciences Inks Amendment with Windtree for PHEXXI SupplyApril 5, 2025 | investing.comEvofem Signs Sourcing Partnership With Windtree, Expects To Reduce Production Cost Of Phexxi By 60%March 28, 2025 | nasdaq.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26, 2025 | prnewswire.comEvofem Biosciences Reports Sales Growth and Strategic AdvancesMarch 24, 2025 | tipranks.comWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductMarch 20, 2025 | globenewswire.comEvofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTOFebruary 13, 2025 | prnewswire.comEvofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024November 16, 2024 | finanznachrichten.deEvofem Biosciences Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comEvofem Biosciences Announces Financial Results for the Third Quarter of 2024November 14, 2024 | prnewswire.comAditxt announces Evofem secures voting agreements with investors for mergerNovember 6, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNAT, ASLN, CWBR, and EVFM Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 07/3/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Conatus Pharmaceuticals NASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.CohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Evofem Biosciences NASDAQ:EVFM$0.01 0.00 (0.00%) As of 07/3/2025 11:39 AM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
